Patent Grant
11357911
This application claims priority to the following US patent applications: U.S. Patent Application No. 61/895,270, filed on Oct. 24, 2013 and entitled “Manifold for the Transferral of Medicaments from Different Vials Without Mis-Channeling;” U.S. Patent Application No. 61/895,279, filed on Oct. 24, 2013 and entitled “Device for Bridging Infusion Sources With Sites of Infusion in a Multi-Channel Infusion System of Two Medicaments;” U.S. Patent Application No. 61/895,288, filed on Oct. 24, 2013 and entitled “Infusion Set or Administration Set for Infusing Two or More Medicaments via an Array of Multiple Catheters or Canulae;” U.S. Patent Application No. 61/932,835, filed on Jan. 29, 2014 and entitled “Multi-infusion Device that allows Unique Loading of Vials for Delivery of Medicaments Without Mis-Channeling;” and U.S. Patent Application No. 62/011,306, filed on Jun. 12, 2014 and entitled “Infusion System for Preventing Mischanneling of Multiple Medicaments.” The contents of the aforementioned applications are incorporated herein by reference.
The present invention relates to a system and method for administering medicaments to a diabetic patient. More particularly, the present invention relates to system and method of preventing the mischanneling of medicaments so as to avoid the accidental administration of the wrong medicament to the diabetic patient.
Diabetes mellitus, often referred to as diabetes, is a chronic condition in which a person has elevated blood glucose levels that result from defects in the body's ability to produce and/or use insulin. There are three main types of diabetes. Type 1 diabetes is a condition wherein the body does not produce insulin and therefore cannot control the amount of sugar in the blood stream. This type of diabetes can be autoimmune, genetic, and/or environmental and usually strikes children and young adults. Type 2 diabetes is a condition wherein the body does not produce or use insulin normally. This type of diabetes accounts for between 90-95% of diabetes cases and is linked to obesity and physical inactivity. Gestational diabetes is a form of glucose intolerance diagnosed during pregnancy and usually resolves spontaneously after delivery.
Insulin is used to control blood sugar in people who have Type 1 and Type 2 diabetes. Insulin is a hormone that helps keep blood glucose levels on target by moving glucose from the blood into the cells of the body. The cells then use glucose for energy. In people who do not have diabetes, the body produces the correct amount of Insulin on its own, whereas the bodies of diabetics do not. There are different types of insulin but they differ only in how quickly they begin to work and how long they continue to control blood sugar or glucose. Insulin is usually needed several times a day, and more than one type of insulin may be needed. Insulin helps control high blood sugar but unfortunately does not cure diabetes.
The number of diagnosed cases of diabetes continues to increase in the U.S. and throughout the world, creating enormous economic and public health consequences. Devices and therapies that improve the quality of life for the diabetic patient are important not only for the patient, but for society at large. One area in which recently developed technologies have been able to improve the standard of care has been in the maintenance of tight control over blood glucose levels. It is well known that if a diabetic patient's blood glucose values can be maintained in a relatively narrow and normal range (e.g., between about 80 milligrams per deciliter (mg/dL) to about 120 mg/dL) the physiologically damaging consequences of unchecked diabetes can be minimized.
Diabetes is managed primarily by controlling the level of glucose in the bloodstream. This level is dynamic and complex and is affected by multiple factors including the amount and type of food consumed and the amount of insulin (which mediates the transport of glucose across cell membranes) in the blood. Blood glucose levels are also sensitive to many different types of things, such as exercise, sleep, stress, smoking, travel, illness, and other psychological and lifestyle factors unique to individual patients. With better blood glucose information, diabetic patients can better control their blood glucose level through a variety of means, including diet, exercise, and medication. For this reason a large industry has developed to provide the diabetic population with ever more convenient and accurate ways to measure blood glucose levels and to deliver insulin to the patient. There are many forms of blood glucose measuring devices; one common type is represented by hand-held electronic meters which receive blood samples via enzyme-based “test strips”, In using these systems, the patient lances a finger or alternate body site to obtain a blood sample, the strip is inserted into a test strip opening in the meter housing, the sample is applied to the test strip and the electronics in the meter convert a current generated by the enzymatic reaction in the test strip to a blood glucose value.
Some diabetic patients require insulin for the treatment of their diabetes, in order to maintain their glucose levels within the desired range. These “insulin-dependent” diabetic patients have traditionally administered insulin doses to themselves subcutaneously via either a hypodermic syringe or with a specialized injector known as an insulin pen. Although these subcutaneous injection methods can deliver insulin at an appropriate time and at an appropriate total dosage, the single bolus aspect of the delivery is unlike a physiological profile of insulin production in the body, which involves a lower rate of insulin entry into the bloodstream, over a more extended time course.
In order to address this issue, conventional techniques have evolved to include insulin pumps. With the insulin pump, a diabetic receives a continuous dosage of insulin from a pump apparatus via an “injection device” mounted on his or her body, Insulin is supplied (e.g., pumped) from the insulin pump through a tube to the injection device. Injection devices generally include a delivery cannula mounted in a subcutaneous manner through the skin of the patient at an infusion site. The injection device typically includes a channel that transmits insulin from an inlet port to the delivery cannula which results in delivery to the subcutaneous tissue layer of the diabetic in which the delivery cannula is located.
Insulin pumps offer significant therapeutic value as they deliver insulin if desired in a more normal physiological manner, with measured doses of insulin being slowly infused over an extended period of time. Further, the rate at which insulin is delivered can be programmed so as to follow standard or individually-modified protocols, thus giving the user even better glucose control over the course of a day. Conventional insulin pumps have evolved to become small in size, which offers easier portability and unobtrusiveness, and with electronic advances, they have evolved to become more fully-featured, and thereby capable of enhanced performance.
As mentioned above, standard-of-care insulin therapies for regulating blood glucose in diabetes typically involve either multiple daily subcutaneous injections or subcutaneous infusion with an insulin pump. Occasionally, the amount of dosed insulin can prove excessive in the sense that it can lead to hypoglycemia or a situation of impending hypoglycemia. To combat and/or reverse such adverse situations, individuals typically consume additional carbohydrates (e.g. sweet juice or glucose tablets) and in some situations can also administer a so-called “rescue dose” of a counter regulatory agent, such as glucagon. In such an application, glucagon is typically reconstituted into solution from an emergency kit and manually administered intramuscularly.
Hence, one traditional approach for managing diabetes is to control blood glucose levels via a control system that automates the transcutaneous delivery of both insulin and glucagon, as needed. Such a control system can, for example, orchestrate the automatic administration of both insulin and glucagon. With such a multi-hormone system, there is a need to fill one infusion reservoir (or infusion cartridge) with one medicament, and another infusion reservoir (or infusion cartridge) with another medicament. During the filling process, each medicament needs to be transferred from a storage vial to the reservoir or cartridge and then ultimately delivered to the patient. Since multiple different hormones having very different physiological effects are being delivered to the patient, it is important to make sure that the correct medicament is being delivered to the patient.
A drawback of the present multi hormonal regimens which employ multiple medicaments is that the patient or other person may accidentally load, transfer and/or administer the incorrect medicament. The accidental administration of the incorrect medicament to the patient can have serious and potentially fatal consequences.
It is thus an object of the present invention to provide a system and method to ensure the proper channeling of medicaments during the loading, transferal or administration process. The proper channeling of medicaments is especially important in the case of insulin and glucagon, since these medicaments produce opposite effects (e.g., lowering versus raising blood sugar levels). If the medicaments are accidentally loaded in the incorrect locations or reservoirs, the control system that automates delivery of the medicaments via the insulin pump can thus deliver the wrong medicament to the patient. Because the wrong medicament would have the opposite of the intended effect, this could not only fail to alleviate the patient's condition, but could make the patient's condition worse. Moreover, this improper channeling could cause a negative feedback loop, wherein the control system attempts to adjust the patient's blood sugar level in one direction, but the delivery of the incorrect medicament causes the blood sugar level to be altered in the opposite direction. Sensing this, the control system can trigger further doses of the wrong medicament in an attempt to control the patient's condition, causing the patient's condition to further deteriorate.
It is thus an object of the present invention to provide a system and method of preventing the administration of the incorrect medicament to the patient.
Exemplary embodiments of the present invention provide a multi-medicament infusion system that helps prevent the mischanneling of medicaments. The system can include an infusion pump, medicament reservoirs, one or more manifold, a multi-channel lumen assembly, and an infusion set. The medicament reservoirs may be sized and shaped differently such that the medicament reservoirs can only be inserted into the infusion pump in a unique or selected configuration. The multi-channel lumen may include feature elements such as connectors or adapters, that mate to corresponding connectors or adapters on the infusion pump and if desired the infusion set only in a unique configuration. Because the various parts of the multi-infusion system may only be connected in the unique configuration, the expected medicaments may be administered appropriately and channeled to the correct infusion sites.
According to one practice of the invention, a system for delivering multiple fluids to a patient is provided and includes at least first and second reservoirs, where each of the reservoirs houses a fluid and has a feature element associated therewith. The feature element of the first reservoir is different than the feature element of the second reservoir. The system also includes at least first and second inlets or ports (functioning at least as inlet ports), where each of the inlet ports has a feature element associated therewith, and wherein the feature element of the first inlet port is different than the feature element of the second inlet port. Further, the feature element of the first reservoir is complementary to the feature element of the first inlet port or a first intermediary coupling piece between the first reservoir and the first inlet port and the feature element of the second reservoir is complementary to the feature element of the second inlet port, such that when assembled the first reservoir is capable of only being fluidly coupled to the first inlet port and the second reservoir is capable of only being fluidly coupled to the second inlet port, thereby preventing mischanneling of the fluid.
According to the system of the present invention, an infusion pump is provided and the first and second inlet ports are formed therein. Alternatively, the first and second inlet ports are manifolds disposed on the outside of the infusion pump or formed in the infusion pump. Additionally, the infusion pump can include a first outlet port fluidly coupled to the first inlet port, and a second outlet port fluidly coupled to the first inlet port.
The first reservoir can house for example a regulating agent, such as insulin, and the second reservoir can house a counter-regulatory agent, such as glucagon.
According to the present invention, the feature element of the first inlet port can comprise a first surface feature and the feature element of the second inlet port can comprise a second surface feature, where the first surface feature is different than the second surface feature. According to one embodiment, the first and second inlet ports each have formed therein a piercing element for piercing the first and second reservoirs, respectively. If desired, the first and second inlet ports can be removably and replaceably coupled together.
The system can also include a first cap element having a feature element associated therewith and is configured to engage at least the feature element of the first inlet port, and a second cap element having a feature element associated therewith and is configured to engage at least the feature element of the second inlet port. The feature element of the first cap element is complementary in shape to the feature element of the first inlet port and the feature element of the second cap element is complementary in shape to the feature element of the second inlet port, such that when assembled the first cap element is capable of only being fluidly coupled to the first inlet port and the second cap element is capable of only being fluidly coupled to the second inlet port. Further, the first and second cap elements simultaneously respectively engage with the first and second reservoirs and the first and second delivery ports so as to secure the reservoirs in place.
The system in addition to the infusion pump can include a multi-channel lumen assembly having a first tube having an inlet port fluidly coupled to the first outlet port of the infusion pump and an outlet port, and a second tube having an inlet port fluidly coupled to the second outlet port of the infusion pump and an outlet port, and an infusion set having a first inlet port fluidly coupled to the outlet port of the first tube and a second inlet port fluidly coupled to the outlet port of the second tube.
According to another practice, the first outlet port of the infusion pump has a feature element associated therewith and the second outlet port of the infusion pump has a feature element associated therewith. The inlet port of the first tube of the multichannel lumen assembly has a feature element associated therewith and the second tube of the multi-channel lumen assembly has a feature element associated therewith. The feature element of the first outlet port of the infusion pump is complementary in shape to the feature element of the inlet port of the first tube and the feature element of the second outlet port of the infusion pump is complementary in shape to the feature element of the inlet port of the second tube, such that when assembled the first outlet port is capable of only being fluidly coupled to the inlet port of the first tube and the second outlet port is capable of only being fluidly coupled to the inlet port of the second tube.
According to still another practice, the outlet port of the first tube of the multichannel lumen assembly has a feature element associated therewith and the outlet port of the second tube of the multi-channel lumen assembly has a feature element associated therewith. Further, the first inlet port of the infusion set has a feature element associated therewith and the second inlet port of the infusion set has a feature element associated therewith. The feature element of the outlet port of the first tube of the multi-channel lumen assembly is complementary in shape to the feature element of the first inlet port and the feature element of the outlet port of the second tube of the multi-channel lumen assembly is complementary in shape to the feature element of the second inlet port, such that when assembled the outlet port of the first tube is capable of only being fluidly coupled to the first inlet port and the outlet port of the second tube is capable of only being fluidly coupled to the second inlet port.
According to yet another embodiment, the inlet port of the first tube has one or more feature elements to serve as a first intermediary coupling piece by attaching to the feature element of the first reservoir and the feature element of the first inlet port, and the inlet port of the second tube has one or more feature elements to serve as a second intermediary coupling piece by attaching to the feature element of the second reservoir and the feature element of the second inlet port. When assembled, the first reservoir is capable of only being fluidly coupled to the inlet port of the first tube and the second reservoir is capable of only being fluidly coupled to the inlet port of the second tube, thereby preventing mischanneling of the fluid.
These and other features and advantages of the present invention will be more fully understood by reference to the following detailed description in conjunction with the attached drawings in which like reference numerals refer to like elements throughout the different views. The drawings illustrate principals of the invention and, although not to scale, show relative dimensions.
The present invention described herein relates to an infusion system 10 for subcutaneously delivering a plurality of medicaments or infusates, and preferably different types of medicaments or infusates, to a patient. Specific examples are set forth below with respect to a dual-medicament delivery and infusion system for delivering multiple medicaments, such as for example insulin and glucagon, to the patient. However, one of ordinary skill in the art will readily recognize that the infusion system 10 of the present invention may be used with other types of medicaments or infusates, and may be used, configured or designed to deliver more than or less than two medicaments.
In a conventional infusion system suitable for delivering a single type of medicament to the patient (e.g., a conventional insulin pump), it is generally unnecessary to ensure that the expected or correct medicament has been properly installed in the expected configuration or orientation within the pump. Because the conventional system utilizes only a single medicament that is typically carefully sourced, there is limited cause for concern that the wrong medicament is used or that the medicament is installed in an incorrect manner.
When increasing the number of medicaments to be delivered to or infused within the patient, however, the correct installation of the medicaments becomes a potential source of problems. Especially in the case of a system for delivering counter-acting medicaments (such as glucagon and insulin), the results of a mis-installed or mischanneled medicament can be harmful or potentially fatal. Furthermore, if the medicaments are to be installed by the end-user (e.g., in the patient's home), it may be quite easy to incorrectly install the medicaments and/or the various parts of the system that channel the medicaments to their infusion sites if the user has no formal medical training.
The present application addresses these and other problems. Exemplary embodiments provide a safe and reliable multi-medicament infusion system that prevents the incorrect installation and mischanneling of medicaments. The systems and methods of the present invention as described herein can be used in an in-patient setting or an outpatient setting, and can be used in the context of an autonomous or semi-autonomous closed-loop glucose control system (e.g. sensor-augmented infusion system).
The medicament reservoirs 16A, 16B may be inserted into the infusion pump 12 via an inlet. The inlet can function as an inlet port, an outlet port or both. For example,
Alternatively or in addition, a manifold 14 may be provided in place of the inlet ports/caps 68. Medicament from the medicament reservoirs may be delivered to the multi-channel lumen 18 through an outlet port of the infusion pump 12.
In some embodiments, the inlet port of the infusion pump 12 (through which the medicament is received by the infusion pump 12) and the outlet port of the infusion pump 12 (through which the medicament is pumped to the multi-channel lumen 18) may be the same. For example, the multi-channel lumen 18 may be provided with an integrated first medicament inlet/outlet interface 85 and an integrated second medicament inlet/outlet interface 87. Specifically, the inlets covered by the connectors 68, 68 can be eliminated and the inlets covered by the connectors 85, 87 thus function as combined inlet/outlet ports. In such an embodiment, the medicament reservoirs 16A, 16B may be inserted into respective ports or openings in the infusion pump 12. The integrated first and second medicament inlet/outlet connectors or interfaces 85, 87 may interface with the inlet/outlet ports or openings of the infusion pump 12 to receive medicaments pumped by the infusion pump 12. The infusion system employing connectors and ports of this type are also illustrated in
The multi-channel lumen assembly 18 can include two or more channels, where each channel is adapted to deliver a particular type of medicament to an appropriate inlet port on the infusion set 20. The multiple channels (e.g., fluid pathways) formed by the multi-channel lumen assembly 18 may be coupled and uncoupled together in order to assist the patient in assembling the infusion system, replacing one or more tubes of the assembly, or preventing the tubes of the lumen assembly from becoming tangled or caught on objects during daily use and during the performance of normal daily activities.
The multiple channels may bridge the span between the infusion pump 12 and the infusion set 20 by independent channels where each channel can be a single or multiple-lumen channel, by channels joined by webbing or by some other manner where each channel can be a single or multiple-lumen channel, or by a single multiple-lumen channel where the enclosed lumens are arranged in an array or as concentric lumens.
The infusion set 20 can connect the multi-channel lumen assembly 18 to a delivery system, such as a cannula, for delivering the medicaments to the user. The infusion set 20 can include one or more infusion ports that adheres to the skin of the patient and which contains one or more piercing elements, such as needles or cannulas, and which are inserted on, into, or under the skin and which can reside there for one to several days before being replaced by a new infusion set.
The illustrated infusion pump 12 can be any suitable infusion pump sized and configured to deliver a plurality of medicaments as set forth herein. The infusion pump 12 may be programmed with suitable logic for controlling the delivery of the medicaments based on measurements associated with a condition of the user. For example, in the case of an infusion pump 12 for delivering medicaments, such as insulin and glucagon, the infusion pump may control the delivery of the medicaments based on real-time measurements of the user's blood glucose level measured from, for example, a glucose sensor (not shown) that is operatively coupled to the patient and if needed to the pump. The infusion pump 10 may be manually operated, semi-autonomous with some manual control by the user, or part of a fully autonomous multi-hormone glucose-control system, an example of which is a closed-loop glucose control system that uses a sensor-augmented infusion pump mechanism to automatically administer both insulin and glucagon or other medicaments. As such, the infusion pump 12 can be coupled if desired to a controller (not shown) that assists with the control and operation of the delivery device. An example of a system and associated control logic suitable for use with the infusion system of the present invention is described in U.S. Pat. No. 7,806,854, assigned to the assignee hereof, the contents of which are herein incorporated by reference.
The infusion pump 12 can be any pump suitable for delivering via a catheter and tubing assembly a plurality of medicaments to the patient. The infusion pump 12 for example can be an ambulatory infusion pump that can deliver the medicament (such as insulin) through the tubing assembly 18 and associated infusion set 20, thereby permitting the subcutaneous infusion of the desired medicine. Features of the illustrated infusion pump 12 may include, for example and without limitation, basal and/or bolus delivery programs, bolus calculation estimators, limit alarms, reminders, visual, vibratory and auditory alarm indications, pump operation logging and analysis, and optionally, a food database to assist in calculating meal carbohydrate amounts. Although not illustrated herein, the infusion pump 12 can communicate via a cable or wirelessly to a computing device. Those of ordinary skill will readily recognize that the computing device can include a controller and other associated hardware and software capable of communicating with or controlling the infusion pump, and providing if desired information or other data to the infusion pump, such as configuration settings and personal data. The computing device may include software for maintaining or storing logs, displaying pump data in text or graphical format and may provide analysis to the user and/or healthcare professionals. The infusion pump can also include a display-screen and an on-board power source for providing power to the pump.
In the illustrated infusion system 10, there are several locations at which a medicament can be mis-installed or mischanneled. For example, the incorrect medicament reservoir can be placed or mounted in the incorrect manifold 14 or coupled to the incorrect inlet port of the infusion pump 12. The outlet ports of the infusion pump 12 can be connected incorrectly to the respective channels of the multi-channel lumen assembly 18, and thus even if the medicament reservoirs were properly installed, they can be improperly channeled to the infusion site. Finally, the end portions or outlets of the multi-channel lumen assembly 18 can be connected to the incorrect inlets of the infusion set 20.
The exemplary embodiments of the present invention address these concerns by providing feature elements and/or mating connectors or adapters on certain components of the infusion system 10. The unique mating connectors and feature elements ensure that each portion of the system can only be connected to the system in a unique way or configuration, thus preventing the mischanneling of medicaments. The exemplary embodiments of the present invention may have the following advantages: (1) the infusion system allows the user to easily connect and disconnect the channels independently from both medicament sources as well as from the infusion ports or sites; (2) the infusion system mitigates the possibility of mischanneling by accidentally connecting the wrong tubing to the wrong medicament source or infusion site (e.g., by having a connector that is disposed between one tube and one pump reservoir of one medicament system differ from the connector of the other tube and reservoir); and (3) the infusion system allows for a single or multistep insertion of the dual-cannula infusion site or port.
One of ordinary skill in the art will understand that the infusion system depicted in
In such an embodiment, the reservoirs 16A, 16B may be bladders in the infusion pump 12 that are manually filled, such as by a syringe. The syringe may include surface features designed to mate with a filling port on the infusion pump 12, such that only one type of syringe is able to fill a respective bladder. In another embodiment, the infusion pump 12 may be of a clamshell design, folding open in order to allow one or more cartridges to be inserted as the reservoirs 16A, 16B, in which case the cartridges may be provided with surface features such that the cartridges may only be inserted into an appropriate slot or port of the infusion pump. In yet another embodiment, the cartridges may be loaded into an intermediate loading device which transfers the fluids from the cartridges to the infusion pump 12, in which case the intermediate loading device may be provided with surface features matching inlet ports of the infusion pump 12.
With reference to
The manifold 14 can be shaped, sized or configured for coupling, either directly or indirectly through any suitable intermediate mechanical device, to the reservoirs 16A and 16B. The reservoirs can be any housing or structure suitable for containing or holding a selected fluid. The fluid holding structure can be flexible or relatively rigid depending upon the application or use of the reservoir. The fluid can be any suitable fluid such as for example a medicament or infusate. Examples of suitable fluid holding structures include vials, cartridges, bladders, ampoules, or other suitable containers for holding the fluid. Moreover, the reservoir can be configured to include a septum as is known in the art. For purposes of simplicity, we reference below the delivery of a medicament. The medicament can include any suitable compound or drug for treating, regulating, controlling or addressing one or more conditions of the patient. In the present embodiment, the condition is diabetes mellitus, although those of ordinary skill will readily recognize that other conditions can be addressed as well. The medicament can include for example a regulating agent, such as insulin, for regulating the blood glucose levels in the patient and/or a counter-regulatory agent, such as glucose or glucagon, for more effective blood glucose regulation in certain circumstances. One of ordinary skill in the art will readily recognize that other type of agents can be used as well.
The present invention provides for a selected feature element or connector/adapter to be disposed on either or both the manifold or reservoir for ensuring that the proper medicament reservoir is coupled to the proper or correct manifold. This arrangement of components helps prevent the accidental coupling of a reservoir containing a specific medicament to an incorrect manifold. For example, according to one practice, the manifold includes two separate manifolds each configured to mate with a specific reservoir. Hence, a first manifold can be adapted to accommodate a first reservoir containing a first medicament, such as insulin, and a second manifold can be adapted to accommodate a second reservoir containing a second medicament, such as glucagon. In this example, it is important to ensure that the glucagon reservoir is not accidentally coupled to the insulin manifold and vice versa.
One or more components of the infusion system, including for example the manifold, reservoir, pump, or any combination of components, can include a selected feature element that ensures the proper coupling together of the components to help prevent the mischanneling or mis-loading of medicaments. The term “feature” or “feature element” as used herein can include any suitable structure, coupler, connector, adapter or feature having any suitable size, shape, dimension, or surface element or surface feature that allows, permits, enables or facilitates the coupling together of one or more system components, such as for example a selected reservoir to a selected manifold or portion of a manifold, whether external to the infusion pump or internal to the infusion pump, in selected ways so as help prevent the mischanneling of medicaments. The feature element can include for example the size, area or volume of a component, such as the volume or size of a chamber defined by the manifold. The feature element is also intended to include any suitable surface feature, which can include for example, any element formed on, within or which protrudes from a surface of one or more components of the infusion system, such as for example the manifold, reservoir, pump, tubes of infusion set, that also allows, enables or facilitates the coupling together of one or more system components. Examples of suitable surface features can be detents, ribs, slots, keys, grooves, holes, corrugations, indentations, or any other suitable mechanical and/or electrical coupling or attaching element. When a surface feature is formed for example on the reservoir or manifold, the present invention contemplates forming a complementary shaped surface feature on the other mating system component or element, thus allowing the reservoir and the manifold to be coupled together. If the corresponding surface feature is absent from the corresponding element, then the reservoir and manifold cannot be coupled together. The feature element is also intended to include any suitable connector, coupler, fastener or adapter that is also adapted and configured to mechanically and/or fluidly couple together one or more components of the infusion system. In some embodiments, two elements (such as the medicament reservoirs 16A, 16B and the infusion pump 12 or lumen 18) may be indirectly coupled to each other through an intermediary coupling piece. For example, the intermediary coupling pieces may be connectors or caps (such as the caps 68, 84, 86) or the inlet ports of lumen 18 (such as the inlet ports 85, 87) that capture the medicament reservoirs 16A, 16B and couple to the infusion pump 12, as described in exemplary embodiments below.
Preferably, the feature elements when employed help form specific dedicated fluid pathways that helps prevent the mischanneling of medicaments and hence helps prevent the accidental administration of an incorrect medicament to the patient.
As illustrated in
Further, the manifolds and reservoirs can have any selected shape, size or design. To that end,
The manifold 14 can also include a cap element 30 that helps seal the top portion of the chamber 26 when attached to the housing 24. The cap element 30 can be coupled or secured to the housing 24 by any suitable mechanism. In the illustrated example, the cap includes a groove 32 formed on an underside of the cap that is adapted to mate with the top edge of the housing.
As shown in
Furthermore, as illustrated, the base portion of the manifolds 14A, 14B can be separate and distinct from each other. Although not shown, the base portions can also be configured to be easily assembled and disassembled. The base portions can be coupled together using known connection techniques, including the use of snap fit features and the like. When designed as such, the based portions allow the patient to configure and customize the infusion system in a manner that best suits the patient's needs by the ability to detach and reattach the base portions as needed or desired.
Alternatively, and according to another practice, the manifolds and the reservoirs can include one or more surface features that helps determine which reservoir is intended to be accommodated in a particular manifold. As illustrated in
Similarly, the second manifold 14B can include one or more surface features, such as ribs 54, that are formed on and extend outwardly from the inner wall 28 into the chamber. The ribs 54 can be spaced at selected locations about the circumference of the inner wall. The second reservoir 16B can also include one or more mating or complementary shaped surface features, such as grooves 56, that are formed within an outer surface of the reservoir and which are spaced at selected locations that correspond to the locations of the ribs 48. Hence, the reservoir 16B having the grooves 56 formed therein is adapted to seat within and mate with the corresponding ribs 54 of the manifold 14B. In the current example, the locations of the ribs 54 and grooves 56 differ from the locations of the ribs 48 and grooves 50. As such, the reservoir 16B is prevented from being mounted within the manifold 14A, and the reservoir 16A is prevented from being mounted within the manifold 14B. This configuration prevents the accidental loading of a medicament reservoir in the incorrect manifold, thus avoiding the accidental administration to the patient of the incorrect medicament.
Those of ordinary skill in the art will readily recognize that many different types and shapes of feature elements and surface features can be employed by the manifold and reservoir of the present invention. For example, although a pair of protruding surface features are employed by the manifolds and a pair of groove style surface features are employed by the reservoirs of the present invention, the surface features can also be reversed where the grooves are formed in the inner wall of the manifolds and the ribs are formed on the outer surface of the reservoirs. Alternatively, the manifold chambers can have different shapes relative to each other and the reservoirs can be configured to have a shape complementary to its associated chamber to allow seating within the manifold. Furthermore, the feature elements can also be formed on the cap portion of the manifold rather than on the housing portion.
The illustrated base portion 38 is a single unitary base such that the manifolds 14A and 14B are coupled thereto and extend outwardly therefrom. Those of ordinary skill in the art will readily recognize that the base portion can also be split into separate portions; one portion associated with each manifold. Moreover, the separate base portions can be configured such that the base portions can be assembled and disassembled as needed.
According to another practice, the feature element can be constructed to include the piercing element rather than have the piercing element formed as part of the manifold. As such, in this potential configuration, the reservoir can be mounted within a manifold, such as for example a manifold formed internally within the infusion pump. A reservoir and a feature element, such as a connector, can be mounted within the manifold. The connector can include a piercing element for piercing the reservoir.
In use, the reservoirs are inserted within the chambers of the manifolds 14. Specifically, the reservoir 16A is mounted within the manifold 14A and the reservoir 16B is mounted within the manifold 14B. After properly seating or docking the medicament reservoir in the manifold, the cap is snapped into position, thus securely capturing the medicament reservoir within the manifold housing 20.
Furthermore, the manifolds 14 allow for automatic air-pressure equalization as fluid is drawn from the reservoirs 16A, 16B. The manifold may also allow a transparent view of the amounts of medicament resident in the reservoirs that are inserted within the chambers of the manifolds. Furthermore, the manifold 12 may detach into separate single manifolds/ports, and may be re-attached, or the manifold can be integrated together, such as on a common base portion.
In order to further prevent the accidental mischanneling or mis-loading of medicaments during the transfer of the medicament from the reservoirs to the infusion pump, the outlet ports of the manifold assembly and/or the inlet ports of the infusion pump can be configured to have different feature elements. According to one practice, each manifold can have an outlet port (e.g., coupler portion 42) that has a feature element that is different than the feature element formed on the outlet port of the other manifold. That is, the shape, size or design of the outlet ports of the manifolds can differ. The outlet ports are adapted to mate with a corresponding inlet port of the infusion pump or a tube having an inlet end that is shaped in a complementary manner to the associated manifold outlet port so as to form a fluid pathway between the manifold and the tube or between the manifold and the infusion pump. This fluid pathway allows the drawing of the medicament from the reservoir for the purpose of filling a corresponding cartridge or reservoir in the infusion pump.
The infusion pump can also have formed at outlet ports selected feature elements, such as connectors or adapters, that are also differently designed or configured so as to mate with a specific tube of the lumen assembly 18. This design feature can be in addition to the unique connecting arrangements of the inlet ports. Nonetheless, the formation of fluid pathways that are specific or unique to particular medicaments serve to help prevent the accidental administration of the wrong medicament to the patient. Further, those of ordinary skill in the art will readily recognize that the feature elements of the infusion system of the present invention can be deployed in multiple parts of the multi-medicament infusion system, such as at the connection between the medicament reservoir 16 and the manifold 14, the connection between the manifold 14 and the infusion pump 12, the connection between the infusion pump 12 and the multi-channel lumen assembly 18, and the connection between the multi-channel lumen assembly 18 and the infusion set 20.
According to another practice, one or more of the connector or cap, pump housing 62, or reservoir may have asymmetric features that lead to dissimilar engagement interfaces in terms of loading a selected reservoir. Specifically, a separate connector or adapter type feature element can be used in connection with the reservoir and/or pump housing to create the dissimilar interface. Examples of suitable asymmetric feature elements, as set forth above, can include slots with inside versus outside threads (matched by their corresponding caps), slots with distinct bayonet style latching mechanisms, slots, reservoirs or manifolds with corresponding docking keys or keyways, or a combination of these features, so as to help prevent the mis-loading and mischanneling of the incorrect medicament.
The feature elements (such as adapters or connectors) may be permanently or temporarily attached to one or more of the medicament reservoirs 16A, 16B so that they are distinguishable in terms of their connector ends, cross-sections, shapes, profiles, grooves, threading, or other properties. As such, each medicament reservoir uniquely matches its corresponding slot in the pump housing and/or uniquely connects to its corresponding infusion tube, including any associated connector, septum, or piercing element. Alternatively, the reservoir can have a neck or head portion that is configured to have a selected feature element (e.g., differently shaped necks) that are designed to match selected connectors employed therewith. The pump housing can further be designed to accommodate a selected connector only at a selected location (e.g., a selected manifold), thus creating fluid specific pathways.
As shown in
The cap can also function as a connector whereby it mates with a selected feature element formed on the reservoir, such as on the neck portion thereof. According to the illustrated embodiment, the cap can optionally include a central passage 70 that is sized and configured to seat over an end or neck portion 58 of a selected reservoir. The reservoir 16A can include a neck portion having a selected size and/or shape that is adapted to seat within the central passage 70 of the cap 68 or designed to couple with the cap. After the reservoir 16A is mounted within the corresponding manifold 14A, the cap 68 is inserted in the inlet port 64 by aligning the pins 76 with the keys or grooves 74, inserting the cap over the end of the appropriate reservoir in the appropriate slot, and then turning the cap to lock the cap to the pump housing. This arrangement serves to ensure that the correct reservoir is mounted and retained within the correct reservoir.
In some embodiments, the cap 68 may mate directly with the reservoir 16A, such as by permanently capturing the neck portion 58 of the reservoir 16A. Alternative or in addition, any combination of elements 68, 86, and 87 may mate with the reservoir 16A. In some embodiments, the neck portion 58 of the reservoir 16A may be provided with a feature that corresponds to a feature on the cap 68, so that the cap 68 may mate with and permanently capture only a single type of reservoir 16A (and not mating with and capturing the other reservoir 16B).
Alternatively or in addition, the cap 68 may mate with a feature of the inlet of the infusion pump 12, such as by mating threading or other non-permanent securing features. The cap 68 may be designed to mate with only one inlet of the infusion pump.
By combining the permanent mating of the cap 68 with one type of reservoir 16A and one inlet of the infusion pump, an appropriate reservoir 16A may be permanently captured by the cap 68 while the cap 68 mates with an appropriate inlet on the infusion pump 12 in a non-permanent manner. Thus, a two-stage mating to prevent mishandling may be accomplished, which may be particularly useful in the case where the reservoirs 16A, 16B are provided by a third party and it may not be possible to provide distinguishing features on the reservoirs 16A, 16B. Further, the cap 68 with the attached reservoir 16A may be removed and discarded when the reservoir 16A is depleted.
The other inlet port 72 of the pump is adapted to receive a separate reservoir containing a different medicament. The reservoir, cap, and pump housing can be configured in a different manner to accept reservoir 16B while simultaneously being unable to accept reservoir 16A. For example, the inlet can mount a standard cap 78 that secures the reservoir 16B within the pump housing and/or mate with a feature element formed on the neck of reservoir 16B. For example, as illustrated, the neck portions of the reservoirs 16A and 16B can be configured differently.
The infusion pump 12 may include one or more pumping mechanisms 61 for dispensing the medicaments from the reservoirs 16A, 16B. In an exemplary embodiment, the pumping mechanism 61 may be a lead screw for actuating a plunger at the rear of each of the reservoirs 16A, 16B. By pushing on the plunger, medicament may be forced out of the front of the reservoirs 16A, 16B. In other embodiments, the pumping mechanisms may include a lever, pneumatically actuated pump, hydraulically actuated pump, electrical pump, or any other device suitable for exerting pressure on, or otherwise dispensing medicament from, the medicament reservoirs 16A, 16B. The pumping device may be driven by a motor 63, such as an electric motor. The motor 63 may be powered, for example, by batteries 65 disposed in the pump housing 62.
In exemplary embodiments, the infusion pump 12 may be provided with hardware and/or software control logic associated with the pumping mechanism 61. For example, one of the medicament reservoirs 16A, 16B may include less medicament than the other reservoir, or may be smaller than the other reservoir. In order to further ensure that the wrong reservoir is not inserted into the wrong inlet port, the logic may prevent the infusion pump 12 from dispensing the medicament if the pumping mechanism 61 fails to make contact with a plunger on the end of one of the reservoirs 16A, 16B after being extended for more than a predetermined threshold distance.
For example, if one of the medicaments is insulin and the other medicament is glucagon, the glucagon may be provided in the medicament reservoir 16A in a smaller amount than the insulin is provided in the medicament reservoir 16B. In one embodiment, the medicament reservoir 16A may include about one-third as much glucagon as the medicament reservoir 16B includes insulin. Even if the reservoirs 16A, 16B are of the same size, the plunger at the rear of the glucagon reservoir 16A will initially be deployed two-thirds of the distance into the medicament reservoir 16A. If the glucagon reservoir 16A is inadvertently inserted into the slot intended for the insulin, then the pumping mechanism 61 will need to extend much further than expected in order to make contact with the plunger at the rear of the medicament reservoir 16A. Once it is determined that the pumping mechanism 61 has extended to or more than the predetermined extension distance, logic in the infusion pump 12 may recognize that a problem has occurred and may prevent medicament from being dispensed. Optionally, an error warning indicating that the wrong reservoir 16A has been inserted into the wrong inlet port may be displayed on a display device of the infusion pump 12.
The above process may be employed with a minimum threshold as well. For instance, if in the above example the insulin reservoir 16B is inadvertently inserted into the inlet slot intended for the glucagon, then the pumping mechanism 61 may extend only a short distance before making contact with the plunger at the rear of the reservoir 16B. Because logic stored in the infusion pump 12 expects that it will be necessary to extend the pumping mechanism more than a minimum threshold distance in order to make contact with the plunger, the infusion pump 12 may prevent medicament from being dispensed and an error warning may be displayed.
Alternatively or in addition to the above embodiments, the pumping mechanism 61 for one of the medicament reservoirs 16A, 16B may be initially deployed at a different distance than the other pumping mechanism 61. In the above example, the pumping mechanism 61 associated with the inlet slot intended for the glucagon reservoir 16A may be initially deployed further than, or in a more extended position than, the pumping mechanism 61 associated with the inlet slot intended for the insulin reservoir 16B. In this case, it may be difficult or impossible to insert the insulin reservoir 16B into the slot intended for the glucagon 16A, since the plunger at the rear of the insulin reservoir 16B will make contact with the pumping mechanism 61 for the glucagon slot before the insulin reservoir 16B is fully inserted. This may provide a further mechanism for preventing the wrong medicament reservoir from being inserted into the wrong inlet slot.
One of ordinary skill in the art will understand that the configuration depicted in
The manifold adapted to receive the reservoir 16A can be sized to accommodate only the reservoir 16A, and the manifold adapted to receive the reservoir 16B can be sized to accommodate only the reservoir 16B. Thus, when the reservoir 16A is seated within the corresponding manifold, the cap 86 is threaded on the male threaded region 82 of the adapter 90. Similarly, when the reservoir 16B is seated within the corresponding manifold, the threaded region 80 of the cap 84 is threaded into the female threaded region 94 of the adapter 88. The adapters, caps and manifolds thus form fluid pathways that are specific to the reservoirs 16A and 16B such that the reservoirs are unable to be mounted within the other manifold. This asymmetric arrangement helps prevent the mis-loading of reservoirs in the incorrect manifold, thus helping to prevent the mischanneling of medicaments.
In some embodiments, there may be multiple points of capture at the inlet or outlet ports of the infusion pump 12. For example, the reservoirs 16A, 16B may be provided with collars or swages 83 that may be permanently or non-permanently captured by one or more prongs or other capture devices placed or formed on the caps 84, 86. The caps may non-permanently attach to the infusion pump 12 through the threading 80, 90. If the caps 84, 86 permanently capture the collars 83 of the medicament reservoirs 16A, 16B, then the medicament reservoirs 16A, 16B may be withdrawn from the infusion pump 12 when the caps 84, 86 are removed from the infusion pump 12.
Another embodiment is shown in
Thus, in this embodiment the inlet ports 72, 64 of the infusion pump 12 serve to receive the medicament reservoirs for pumping by the infusion pump 12, and furthermore serves as the outlet ports of the infusion pump 12. Accordingly, the interface between the lumen assembly 18 with an internal needle 36 and the inlet ports 72, 64 of the infusion pump 12 forms an integrated inlet/outlet port for the infusion pump 12.
The embodiments of
When the tubes of the multi-channel lumen assembly are coupled to the outlet ports as described above, the infusion system creates a pair of specific, dedicated and non-interchangeable fluid pathways. The first tube that is coupled to the male connector can only be connected to the outlet port 102 and the second tube that is coupled to the female connector can only be coupled to the outlet port 104.
A similar feature element can be coupled to the outlet port 104. Specifically, the outlet port 104 has the first portion 140 of the feature element attached thereto. The first feature element can also have a base portion 144 having attached thereto the female connector portion 134 and the male connector portion 136. The corresponding second portion 142 of the feature element can be coupled to the second tube of the multi-channel lumen assembly 18. The second feature element portion 142 also includes a base portion 144 having attached thereto a female connector portion 134 and a male connector portion 136, where the positions of the male and female connector portions are reversed so as to be able to properly engage the connector portions of the first feature element portion 140. In order to couple the two connector portions 140, 142 together, the male and female portions of the first portion 140 are inserted into the corresponding male and female portions of the second portion 142 so as to lock the two portions together. Further, the first and second portions 140, 142 of the feature element coupled to the first outlet 102 and the first tube of the multi-channel lumen assembly can have a first selected size that is smaller than the size of the connector portions 140, 142 coupled to the second outlet port 104, as shown. This size difference ensures that the first tube can only be coupled to the first outlet 102 and that the second tube can only be coupled to the second outlet 104. Similar to the connectors 114, 116, 124, and 126, when the tubes of the multi-channel lumen assembly are coupled to the outlet ports as described above, the infusion system creates a pair of specific and non-interchangeable fluid pathways.
The first and second portions 140, 142 of the feature element can also be configured to include additional features such as unique keys or grooves such that they uniquely engage with the ends of the connectors that are distal (i.e., attached to the tubes) to the infusion pump and that are of matching sizes and shapes.
With reference to
The illustrated multi-channel lumen assembly 18 includes first and second tubes 150 and 152, respectively, forming medicament passages or channels. For example, the first tube 150 forms a medicament channel 154 and the second tube 152 forms a medicament channel 156. As described above in connection with
The tubes 150 and 152 of the multi-channel lumen assembly 18 can be configured so as to be able to be coupled together and then, if desired, be detached or decoupled from each other. This can preferably be done repeatedly. As shown in
Furthermore, as shown in
The infusion set 20 of the present invention includes a multi-channel infusion device where each channel infuses a medicament into the patient. The channels are connected to the infusion sites by way of asymmetric positioning feature elements that help prevent the mischanneling of medicaments. The medicaments can be supplied from a single or multichannel system or directly from one or more medicament sources, such as a pumping system having one or more external or internal medicament reservoirs. The infusion set infuses medicaments either intradermally, transdermally, subcutaneously, and/or percutaneously.
The multi-channel lumen assembly 18 is coupled to the infusion set 20. The infusion pump side 166 of the multi-channel lumen assembly 18 can include one or more feature elements, as described above in connection with
The illustrated infusion set 20 includes a base portion 192 that seats the medicament delivery components of the infusion set. The infusion set can include one or more infusion sites having associated therewith one or more piercing elements. The piercing elements can be formed from any suitable material, including metal and non-metal materials. According to one embodiment, the delivery components can include multiple piercing elements, such as first and second spatially separated cannulas 196A and 196B, a portion of which protrude from an underside or bottom surface 198 of a common base 192. The cannulas form first and second medicament infusion sites 182 and 184 from the common base. The cannulas can be attached to the base portion 192 via a support structure 202. The support structure forms inlet ports 206A and 206B. The connector ends 174, 178 of the tubes of the multi-channel lumen assembly 18 are adapted to couple with the inlet ports 206A, 206B, respectively. We describe the embodiments herein as employing cannulas for the sake of simplicity, although those of ordinary skill in the art will recognize that other types of piercing elements can also be used. Moreover, the infusion sites can be formed from a common base 192 or from separate base elements,
The connector ends 174, 178 and/or the inlet ports 206A, 206B can have the feature elements formed thereon. As shown for example in
The medicaments are delivered to the patient at the infusion sites 182, 184 by the cannulas 196A, 196B. As shown in
Those of ordinary skill in the art will readily recognize that the cannulas 196A, 196B in the infusion set 20 can be inserted to the same or different depths under the skin. Moreover, the cannulas can have different lengths, shapes, and profiles. Those of ordinary skill in the art will also recognize that the medicaments can be infused into the patient by mechanisms other than the illustrated piercing elements, such as for example by micropore transfer via a transdermal tape activated by chemical, electrical or other means.
A selected cover 190 can be mounted to the base portion 192 be way of, for example, a hinge. The cover 190 serves to cover and hence protect the medicament delivery components of the infusion set 20. Alternatively, the cover 190 can be a static lid, and can if desired be transparent or opaque. The infusion set could also be constructed without a cover. An adhesive can be mounted to the bottom surface 198 of the base 192 so as to secure the infusion set to the infusion site selected by the patient.
The present invention thus contemplates a multi-channel infusion set 20 where each channel infuses a medicament and a manner of connecting to plural infusion sites that uses asymmetric positioning features to prevent the mischanneling of medicaments. The multiple channels of the multi-channel lumen assembly 18 can bridge the span between the infusion sources and the sites of infusion by way of separate, independent channels (where each channel can be a single channel or a multiple-lumen channel), or by way of channels that are joined or coupled together by webbing or by some other manner. The infusion set can also employ one or more septums that prevent the unwanted leaking of medicaments when connecting and disconnecting the ports from the multi-channel lumen assembly 18.
The present invention mitigates the possibility of mischanneling by connecting the wrong tubing to the wrong infusion cannula by using feature elements having different geometrical, dimensional, and/or positioning physical features that are unique to each medicament source and channel in a manner that uniquely matches the infusion set connection interfaces. The infusion set 20 can be connected, disconnected, or reconnected from the multiple channels in a single engagement step or separately, and the connection provides a secure fluid path from each channel into the infusion sites. The connection between the channels and the infusion set can be released, separately for each channel, and re-connected for multiple use. The infusion set can itself house a channeling system that employs independent channels (where each channel can be a single or multiple-lumen channel), or a single multiple-lumen channel (where the enclosed lumens are arranged in an array, or as concentric lumens), or by any combination of the above.
The illustrated infusion system 10 of the present invention provides for one or more selected feature elements or connectors to be disposed on the pump housing, the reservoir, and the connector for ensuring that the proper medicament reservoir is coupled to the proper or correct manifold of the infusion pump 12. This arrangement of components helps prevent the accidental coupling of a reservoir containing a specific medicament to an incorrect manifold. For example, according to one practice, the pump includes two separate manifolds each configured to mate with a specific medicament reservoir. Hence, a first manifold can be adapted to accommodate a first reservoir containing a first medicament, such as insulin, and a second manifold can be adapted to accommodate a second reservoir containing a second medicament, such as glucagon. In this example, it is important to ensure that the glucagon reservoir is not accidentally coupled to the insulin manifold and vice versa. The unique mating connectors and feature elements thus ensure that each portion of the system can only be connected to the system in a unique way or selected configuration, thus preventing the accidental mischanneling of medicaments.
The connectors 230, 232 can have formed therein a piercing element for piercing a septum formed as part of the neck or swage of the reservoirs. The piercing element can be formed as part of a piercing element assembly that seats within a central opening 240 formed in the connector,
The illustrated connector 230 can also include one or more feature elements in the form of a plurality of surface features 236, 238 that extend outwardly from an outer surface of the connector 230. The surface features can include a plurality of tabs or detents, a subset of which is radially movable relative to the connector housing. According to one practice, the tabs 238 are formed on the outer surface of the connector housing and are fixed in place. That is, the tabs are not radially movable relative to the connector housing. The tabs 236 as shown in
As shown in
Those of ordinary skill in the art will readily recognize that any suitable structure can be employed that is capable of moving the exposed portion of the tabs 236 between the extended and retracted positions upon insertion of the neck of the reservoir into the chamber 234 of the connector 230. According to one practice, the movable tabs 236 can have an elongated, slightly arcuate main body 236A which is attached at one end 236B to the housing of the connector. The opposed free end of the tab extends outwardly through the aperture 246 formed in the sidewall of the housing. In this configuration, the tab is disposed in the extended position. The arcuate structure of the tab provides for a selected amount of resilience and elasticity such that as the reservoir is inserted into the chamber and engages with the tab main body 236A, the flexible tab bends by a selected amount such that the free end portion of the tab that extends through the aperture 246 is retracted inwardly into the chamber 234 and hence into the retracted position. Other tab designs can also be employed in the present invention, including designs where the tab main body has an angled cam surface such that the tab pivots between the retracted and extended positions.
Once the reservoir 16A and the connector 230 are attached together, the combined unit can be mounted within the corresponding port or inlet of the infusion pump 12. According to one practice, the inlet 228 functions as a combined inlet/outlet port or aperture. The inlet 228 preferably has one or more feature elements associated therewith. In the illustrated embodiment, the inlet 228 has a pair of keys or slots 248,
As illustrated in
The illustrated connector 232 can also include one or more feature elements in the form of a plurality of surface features 242, 244 that extend outwardly from an outer surface of the connector housing 254. The surface features can include a plurality of tabs or detents, a subset of which is radially movable relative to the connector housing. According to one practice, the tabs 244 are also formed on the outer surface of the connector housing and are fixed in place. That is, the tabs 244 are not radially movable into the housing. The tabs 242 are configured as movable tabs that can be radially moved between an extended position, where the tabs extend outwardly from the connector housing outer surface 254 through the aperture 246, and a retracted position, where the tabs are primarily disposed within the chamber formed in the housing (similar to chamber 234). The tabs 244 can be placed on or extend outwardly from the connector housing outer surface at any suitable location and preferably are placed at positions that correspond with the location of feature elements formed on a corresponding inlet or port (e.g., inlet port) of the infusion pump housing, such as port 226. The operation and function of the movable tabs is similar or identical to that described above in connection with connector 230, and as illustrated for example in
When the connector 232 is separately disposed relative to the reservoir, the tabs 242, 244 extend radially outwardly from the housing. When the connector is coupled to the reservoir 16B, the neck portion engages the movable tabs 242 or any other suitable cooperating structure to move the tabs 242 from the extended position into the retracted position. When coupled together in this manner, the connection between the reservoir and the connector can be non-permanent or permanent in nature, and the reservoir is preferably permanently retained or coupled to the connector. The tabs 244 can also be configured similar to the tabs 236,
Once the reservoir 16B and the connector 232 are attached, the combined unit can be mounted within the corresponding port or inlet of the infusion pump 12. According to one practice, the inlet 226 functions as a combined inlet/outlet port or aperture. The inlet 226 preferably has one or more feature elements associated therewith. In the illustrated embodiment, the inlet 226 has a pair of keys or slots 250,
Those of ordinary skill in the art will readily recognize that the inlets 226, 228 can have feature elements of any suitable design or shape, and any suitable number of feature elements can be provided on the connectors 230, 232 and at any suitable location.
According to another practice, the connector can be configured so that there is no rotation needed to attach the connector to the pump housing. An embodiment suitable for this purpose is illustrated in
The connector housing 262 has a central opening or passage 268 that is adapted to accommodate a piercing element assembly 270. The piercing element assembly 270 includes a piercing element, such as a needle 272, that is in fluid communication with a channel or lumen 274. The lumen can form part of the multi-channel lumen assembly 18. The piercing element assembly 270 can be secured to the connector 260 and within the opening 268 by any suitable means known to those of ordinary skill in the art, such as by a suitable adhesive.
A bottom portion of the connector housing 262 has a connection assembly that includes a plurality of flexible retaining fingers or tabs 276. The retaining tabs have an inner surface that has a cam feature or surface 278 formed thereon. The cam feature is adapted to engage with a neck portion 83 of the reservoir 16A. As the neck portion is inserted into the opening or chamber 264 formed or defined by the retaining tabs 276 and the inner surface of the housing 262, the neck engages the cam surfaces and serves to flex or bend the retaining tabs in a radially outward direction as the neck travels axially along the cam surface. Once the neck portion of the reservoir passes the cam surface (i.e., disengages from the cam surface), the neck portion then seats in an annular groove 280. When the neck portion 83 is seated in the groove 280, the reservoir 16A is captured and retained by the connector 260.
As further illustrated in
The retaining tabs 276 or a selected subset of the retaining tabs can have a cam or securing feature 282 formed on an outer surface thereof. The cam feature 282 is formed at a location that is axially spaced from the groove 280 so as to allow the retaining tabs to flex under selected conditions without allowing the reservoir 16A to disengage from the connector 260. The cam feature 282 has an angled surface, similar to the cam feature 278, that allows the connector 260 when inserted within the inlet 258 to squeeze or move the retaining tabs radially inwardly to allow the cam feature to travel along the axial length of the inlet. When fully inserted within the inlet 258, the cam features 282 engage an underside or undercut portion of the pump housing 284. This securing technique allows the connector to be attached to the pump housing without requiring rotation of the connector. To remove or disengage the connector 260 from the pump housing, the user applies radially inward pressure (i.e., squeezes) to the grip sections 266. The application of this radially inward force serves to disengage the cam feature from the undercut 284 by moving the cam feature radially inwardly and into the inlet. This allows the user to disengage the connector from the pump and thus remove the reservoir from the manifold formed within the pump housing.
In a multi-medicament infusion system according to the teachings of the present invention, the pump housing can include a pair of inlets as set forth above in connection with other embodiments. The inlets can have different feature elements relative to each other. According to one practice, the inlets can have different sizes relative to each other such that only a connector having the same size and hence having a corresponding or complementary surface feature can be coupled thereto. Additionally or alternatively, the reservoirs can include collars having different surface features, such as different sizes or shapes. These various feature elements help prevent the accidental mischanneling of medicament to the user by preventing the accidental loading of a selected medicament reservoir in the incorrect manifold.
It will thus be seen that the invention efficiently attains the objects set forth above, among those made apparent from the preceding description. Since certain changes may be made in the above constructions without departing from the scope of the invention, it is intended that all matter contained in the above description or shown in the accompanying drawings be interpreted as illustrative and not in a limiting sense.
It is also to be understood that the following claims are to cover all generic and specific features of the invention described herein, and all statements of the scope of the invention which, as a matter of language, might be said to fall therebetween. Having described the invention, what is claimed as new and desired to be secured by Letters Patent is:
This application is a continuation of U.S. application Ser. No. 15/031,512, filed Apr. 22, 2016, which is a 35 U.S.C. 371 national stage filing of International Application PCT/US2014/062186, filed Oct. 24, 2014, which claims priority to U.S. Provisional Application No. 61/895,270 filed on Oct. 24, 2013, U.S. Provisional Application No. 61/895,279, filed Oct. 24, 2013, U.S. Provisional Application No. 61/895,288, filed Oct. 24, 2013, U.S. Provisional Patent Application No. 61/932,835 filed Jan. 29, 2014, and U.S. Provisional Application No. 62/011,306 filed Jun. 12, 2014, in the United States. The contents of the aforementioned applications are hereby incorporated by reference in their entireties.
This invention was made with government support under Contract No. DK085633 awarded by the National Institutes of Health. The government has certain rights in the invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1930929 | Eisenberg | Oct 1933 | A |
| 3807467 | Tascher et al. | Apr 1974 | A |
| 4150673 | Watt | Apr 1979 | A |
| 4253501 | Ogle | Mar 1981 | A |
| 4515584 | Abe | May 1985 | A |
| 4585439 | Michel | Apr 1986 | A |
| 4608042 | Vanderveen | Aug 1986 | A |
| 4675006 | Hrushesky | Jun 1987 | A |
| 5085643 | Larkin et al. | Feb 1992 | A |
| 5147323 | Haber | Sep 1992 | A |
| 5243982 | Mostl | Sep 1993 | A |
| 5298023 | Haber | Mar 1994 | A |
| 5356380 | Hoekwater et al. | Oct 1994 | A |
| 5411480 | Kriesel | May 1995 | A |
| 5472403 | Cornacchia | Dec 1995 | A |
| 5505704 | Pawelka | Apr 1996 | A |
| 5522803 | Teissen-Simony | Jun 1996 | A |
| 5529463 | Layer | Jun 1996 | A |
| 5545152 | Funderburk et al. | Aug 1996 | A |
| 5616124 | Hague et al. | Apr 1997 | A |
| 5916494 | Widman et al. | Jun 1999 | A |
| 5954697 | Srisathapat et al. | Sep 1999 | A |
| 5961494 | Hogan | Oct 1999 | A |
| 5971972 | Rosenbaum | Oct 1999 | A |
| 6106498 | Friedli et al. | Aug 2000 | A |
| 6132416 | Broselow | Oct 2000 | A |
| 6248067 | Causey, III et al. | Jun 2001 | B1 |
| 6259587 | Sheldon et al. | Jul 2001 | B1 |
| 6360784 | Philippens et al. | Mar 2002 | B1 |
| 6362591 | Moberg | Mar 2002 | B1 |
| 6368314 | Kipfer et al. | Apr 2002 | B1 |
| 6390130 | Guala | May 2002 | B1 |
| 6485465 | Moberg et al. | Nov 2002 | B2 |
| 6551276 | Mann et al. | Apr 2003 | B1 |
| 6551298 | Zhang et al. | Apr 2003 | B1 |
| 6554798 | Mann et al. | Apr 2003 | B1 |
| 6555986 | Moberg | Apr 2003 | B2 |
| 6558320 | Causey, III et al. | May 2003 | B1 |
| 6572545 | Knobbe et al. | Jun 2003 | B2 |
| 6585695 | Adair et al. | Jul 2003 | B1 |
| 6620138 | Marrgi et al. | Sep 2003 | B1 |
| 6641533 | Causey, III et al. | Nov 2003 | B2 |
| 6652483 | Slate | Nov 2003 | B2 |
| 6656148 | Das et al. | Dec 2003 | B2 |
| 6659980 | Moberg et al. | Dec 2003 | B2 |
| 6719728 | Mason et al. | Apr 2004 | B2 |
| 6736797 | Larsen et al. | May 2004 | B1 |
| 6752787 | Causey, III et al. | Jun 2004 | B1 |
| 6801420 | Talbot et al. | Oct 2004 | B2 |
| 6809653 | Mann et al. | Oct 2004 | B1 |
| 6811534 | Bowman et al. | Nov 2004 | B2 |
| 6821421 | Murakami | Nov 2004 | B2 |
| 6854620 | Ramey | Feb 2005 | B2 |
| 6872200 | Mann et al. | Mar 2005 | B2 |
| 6878132 | Kipfer | Apr 2005 | B2 |
| 6936029 | Mann et al. | Aug 2005 | B2 |
| 6939329 | Verkaart | Sep 2005 | B1 |
| 6958705 | Lebel et al. | Oct 2005 | B2 |
| 6960198 | Sarmiento | Nov 2005 | B2 |
| 6979326 | Mann et al. | Dec 2005 | B2 |
| 6997920 | Mann et al. | Feb 2006 | B2 |
| 7025226 | Ramey | Apr 2006 | B2 |
| 7025743 | Mann et al. | Apr 2006 | B2 |
| 7098803 | Mann et al. | Aug 2006 | B2 |
| 7109878 | Mann et al. | Sep 2006 | B2 |
| 7187528 | Talbot et al. | Mar 2007 | B2 |
| 7193521 | Moberg et al. | Mar 2007 | B2 |
| 7281314 | Hess et al. | Oct 2007 | B2 |
| 7285105 | Kim et al. | Oct 2007 | B2 |
| 7291133 | Kindler et al. | Nov 2007 | B1 |
| 7324012 | Mann et al. | Jan 2008 | B2 |
| 7342508 | Morgan et al. | Mar 2008 | B2 |
| 7460350 | Talbot et al. | Dec 2008 | B2 |
| 7534226 | Mernoe et al. | May 2009 | B2 |
| 7602310 | Mann et al. | Oct 2009 | B2 |
| 7621893 | Moberg | Nov 2009 | B2 |
| 7625354 | Hochman | Dec 2009 | B2 |
| 7628772 | McConnell et al. | Dec 2009 | B2 |
| 7628782 | Adair et al. | Dec 2009 | B2 |
| 7648494 | Kornerup et al. | Jan 2010 | B2 |
| 7654127 | Krulevitch et al. | Feb 2010 | B2 |
| 7655618 | Green et al. | Feb 2010 | B2 |
| 7658734 | Adair et al. | Feb 2010 | B2 |
| 7678762 | Green et al. | Mar 2010 | B2 |
| 7678763 | Green et al. | Mar 2010 | B2 |
| 7683027 | Green et al. | Mar 2010 | B2 |
| 7708717 | Estes et al. | May 2010 | B2 |
| 7749185 | Wilson | Jul 2010 | B2 |
| 7760481 | Talbot et al. | Jul 2010 | B2 |
| 7766873 | Moberg et al. | Aug 2010 | B2 |
| 7776030 | Estes et al. | Aug 2010 | B2 |
| 7789859 | Estes et al. | Sep 2010 | B2 |
| 7794427 | Estes et al. | Sep 2010 | B2 |
| 7794428 | Estes et al. | Sep 2010 | B2 |
| 7815602 | Mann et al. | Oct 2010 | B2 |
| 7819843 | Mann et al. | Oct 2010 | B2 |
| 7831310 | Lebel et al. | Nov 2010 | B2 |
| 7833196 | Estes et al. | Nov 2010 | B2 |
| 7879010 | Hunn et al. | Feb 2011 | B2 |
| 7879026 | Estes et al. | Feb 2011 | B2 |
| 7887512 | Estes et al. | Feb 2011 | B2 |
| 7892206 | Moberg et al. | Feb 2011 | B2 |
| 7914449 | Kouchi et al. | Mar 2011 | B2 |
| 7922708 | Estes et al. | Apr 2011 | B2 |
| 7951112 | Patzer | May 2011 | B2 |
| 7967785 | Morgan et al. | Jun 2011 | B2 |
| 7981084 | Estes et al. | Jul 2011 | B2 |
| 7981105 | Adair et al. | Jul 2011 | B2 |
| 7988683 | Adair et al. | Aug 2011 | B2 |
| 7998111 | Moberg et al. | Aug 2011 | B2 |
| 7998131 | Adair et al. | Aug 2011 | B2 |
| 8004422 | Hess et al. | Aug 2011 | B2 |
| 7938803 | Mernoe et al. | Oct 2011 | B2 |
| 8034026 | Grant et al. | Oct 2011 | B2 |
| 8057436 | Causey et al. | Nov 2011 | B2 |
| 8062257 | Moberg et al. | Nov 2011 | B2 |
| 8065096 | Moberg et al. | Nov 2011 | B2 |
| 8088096 | Lauchard et al. | Jan 2012 | B2 |
| 8105279 | Mernoe et al. | Jan 2012 | B2 |
| 8106534 | Spurlin et al. | Jan 2012 | B2 |
| 8142397 | Patzer | Mar 2012 | B2 |
| 8167846 | Chong et al. | May 2012 | B2 |
| 8177767 | Kristensen et al. | May 2012 | B2 |
| 8182447 | Moberg et al. | May 2012 | B2 |
| 8192394 | Estes et al. | Jun 2012 | B2 |
| 8197444 | Bazargan et al. | Jun 2012 | B1 |
| 8206350 | Mann et al. | Jun 2012 | B2 |
| 8206353 | Chong et al. | Jun 2012 | B2 |
| 8211059 | Kriesel | Jul 2012 | B2 |
| 8211062 | Estes et al. | Jul 2012 | B2 |
| 8251959 | Johner et al. | Aug 2012 | B2 |
| 8257345 | Adair et al. | Sep 2012 | B2 |
| 8267893 | Moberg et al. | Sep 2012 | B2 |
| 8273061 | McConnell et al. | Sep 2012 | B2 |
| 8282601 | Mernoe et al. | Oct 2012 | B2 |
| 8287495 | Michaud et al. | Oct 2012 | B2 |
| 8287516 | Kornerup et al. | Oct 2012 | B2 |
| 8298184 | DiPerna et al. | Oct 2012 | B2 |
| 8303572 | Adair et al. | Nov 2012 | B2 |
| 8372039 | Mernoe et al. | Feb 2013 | B2 |
| 8409142 | Causey et al. | Apr 2013 | B2 |
| 8430847 | Mernoe et al. | Apr 2013 | B2 |
| 8430849 | Smith et al. | Apr 2013 | B2 |
| 8454575 | Estes et al. | Jun 2013 | B2 |
| 8469942 | Kow et al. | Jun 2013 | B2 |
| 8475408 | Mernoe et al. | Jul 2013 | B2 |
| 8480623 | Mernoe et al. | Jul 2013 | B2 |
| 8483980 | Moberg et al. | Jul 2013 | B2 |
| 8500716 | Adair et al. | Aug 2013 | B2 |
| 8512276 | Talbot et al. | Aug 2013 | B2 |
| 8512289 | Chong et al. | Aug 2013 | B2 |
| 8523803 | Favreau | Sep 2013 | B1 |
| 8551045 | Sie et al. | Oct 2013 | B2 |
| 8551046 | Causey et al. | Oct 2013 | B2 |
| 8556856 | Bazargan et al. | Oct 2013 | B2 |
| 8556866 | Krulevitch et al. | Oct 2013 | B2 |
| 8562565 | Fonacier et al. | Oct 2013 | B2 |
| 8562587 | Kovatchev et al. | Oct 2013 | B2 |
| 8568349 | Shergold | Oct 2013 | B2 |
| 8573027 | Rosinko et al. | Nov 2013 | B2 |
| 8579813 | Causey, III et al. | Nov 2013 | B2 |
| 8597269 | Chong et al. | Dec 2013 | B2 |
| 8603026 | Favreau | Dec 2013 | B2 |
| 8603027 | Favreau | Dec 2013 | B2 |
| 8603033 | Bazargan et al. | Dec 2013 | B2 |
| 8613726 | Causey, III et al. | Dec 2013 | B2 |
| 8613731 | Hansen et al. | Dec 2013 | B2 |
| 8617110 | Moberg et al. | Dec 2013 | B2 |
| 8622966 | Causey, III et al. | Jan 2014 | B2 |
| 8628510 | Bazargan et al. | Jan 2014 | B2 |
| 8641671 | Michaud et al. | Feb 2014 | B2 |
| 8647074 | Moberg et al. | Feb 2014 | B2 |
| 8647296 | Moberg et al. | Feb 2014 | B2 |
| 8663103 | Causey, III et al. | Mar 2014 | B2 |
| 8674288 | Hanson et al. | Mar 2014 | B2 |
| 8679060 | Mernoe et al. | Mar 2014 | B2 |
| 8681010 | Moberg et al. | Mar 2014 | B2 |
| 8696633 | Estes et al. | Apr 2014 | B2 |
| 8747368 | Mernoe et al. | Jun 2014 | B2 |
| 8747369 | Mernoe et al. | Jun 2014 | B2 |
| 8758323 | Michaud et al. | Jun 2014 | B2 |
| 8771229 | Amirouche et al. | Jul 2014 | B2 |
| 8777901 | Smith et al. | Jul 2014 | B2 |
| 8790307 | Amirouche et al. | Jul 2014 | B2 |
| 8821442 | Haaar | Sep 2014 | B2 |
| 8823528 | Blomquist | Sep 2014 | B2 |
| 8834420 | Estes et al. | Sep 2014 | B2 |
| 8841012 | Fonacier et al. | Sep 2014 | B2 |
| 8864726 | Halili et al. | Oct 2014 | B2 |
| 8864737 | Hasegawa et al. | Oct 2014 | B2 |
| 8864739 | Moberg et al. | Oct 2014 | B2 |
| 8870829 | Halili et al. | Oct 2014 | B2 |
| 8876770 | Kraft | Nov 2014 | B2 |
| 8900206 | Halili et al. | Dec 2014 | B2 |
| 8905972 | Smith et al. | Dec 2014 | B2 |
| 8915879 | Smith et al. | Dec 2014 | B2 |
| 8936573 | Blomquist | Jan 2015 | B2 |
| 8945068 | Halili et al. | Feb 2015 | B2 |
| 8974435 | Friedli | Mar 2015 | B2 |
| 8992475 | Mann et al. | Mar 2015 | B2 |
| 8992507 | Aeschlimann et al. | Mar 2015 | B2 |
| 8998840 | Hanson et al. | Apr 2015 | B2 |
| 8998842 | Lauchard et al. | Apr 2015 | B2 |
| 8998856 | Eggert | Apr 2015 | B2 |
| 8998858 | Chong et al. | Apr 2015 | B2 |
| 9011371 | Moberg et al. | Apr 2015 | B2 |
| 9033925 | Moberg et al. | May 2015 | B2 |
| 9033951 | Kow et al. | May 2015 | B2 |
| 9050406 | Kow et al. | Jun 2015 | B2 |
| 9101710 | Yavorsky et al. | Aug 2015 | B2 |
| 9101715 | Causey, III et al. | Aug 2015 | B2 |
| 9107999 | Moberg et al. | Aug 2015 | B2 |
| 9114209 | Estes et al. | Aug 2015 | B2 |
| 9114213 | Murakami et al. | Aug 2015 | B2 |
| 9119917 | Blomquist | Sep 2015 | B2 |
| 9132228 | Yan | Sep 2015 | B2 |
| 9173998 | Rosinko et al. | Nov 2015 | B2 |
| 9180242 | Metzmaker et al. | Nov 2015 | B2 |
| 9180243 | Michaud | Nov 2015 | B2 |
| 9180254 | Avery et al. | Nov 2015 | B2 |
| 9184490 | Crouther et al. | Nov 2015 | B2 |
| 9194388 | Laermer | Nov 2015 | B2 |
| 9205192 | Estes et al. | Dec 2015 | B2 |
| 9211376 | Kouyoumjian et al. | Dec 2015 | B2 |
| 9211377 | DiPerna et al. | Dec 2015 | B2 |
| 9216249 | Smith et al. | Dec 2015 | B2 |
| 9220835 | Cane' | Dec 2015 | B2 |
| 9250106 | Rosinko et al. | Feb 2016 | B2 |
| 9272009 | Spencer | Mar 2016 | B2 |
| 9283318 | Yavorsky et al. | Mar 2016 | B2 |
| 9295826 | Bertrand et al. | Mar 2016 | B2 |
| 9308320 | Smith et al. | Apr 2016 | B2 |
| 9308321 | Alderete et al. | Apr 2016 | B2 |
| 9314569 | Causey et al. | Apr 2016 | B2 |
| 9320849 | Smith et al. | Apr 2016 | B2 |
| 9327073 | Moberg et al. | May 2016 | B2 |
| 9335910 | Farnan et al. | May 2016 | B2 |
| 9339639 | Halili et al. | May 2016 | B2 |
| 9344024 | Favreau | May 2016 | B2 |
| 9345643 | Okiyama | May 2016 | B2 |
| 9364608 | Moberg et al. | Jun 2016 | B2 |
| 9379652 | Favreau | Jun 2016 | B2 |
| 9379653 | Favreau | Jun 2016 | B2 |
| 9381297 | Brown et al. | Jul 2016 | B2 |
| 9381300 | Smith et al. | Jul 2016 | B2 |
| 9393399 | Yavorsky et al. | Jul 2016 | B2 |
| 9415157 | Mann et al. | Aug 2016 | B2 |
| 9427519 | Kraft et al. | Aug 2016 | B2 |
| 9433731 | Trock et al. | Sep 2016 | B2 |
| 9433732 | Moberg et al. | Sep 2016 | B2 |
| 9433733 | Moberg et al. | Sep 2016 | B2 |
| 9452255 | Tieck et al. | Sep 2016 | B2 |
| 9452256 | Tieck et al. | Sep 2016 | B2 |
| 9463309 | Yavorsky et al. | Oct 2016 | B2 |
| 9494147 | Chong et al. | Nov 2016 | B2 |
| 9498573 | Smith et al. | Nov 2016 | B2 |
| 9514518 | Gillespie et al. | Dec 2016 | B2 |
| 9517299 | Tieck et al. | Dec 2016 | B2 |
| 9517301 | Estes et al. | Dec 2016 | B2 |
| 9533132 | Halili et al. | Jan 2017 | B2 |
| 9539385 | Mathys | Jan 2017 | B2 |
| 9539388 | Causey et al. | Jan 2017 | B2 |
| 9554967 | Moia et al. | Jan 2017 | B2 |
| 9579452 | Adair et al. | Feb 2017 | B2 |
| 9592339 | Zhou | Mar 2017 | B2 |
| 9597462 | Moore | Mar 2017 | B2 |
| 9610431 | Halili et al. | Apr 2017 | B2 |
| 9629992 | Halili et al. | Apr 2017 | B2 |
| 9636453 | Monirabbasi et al. | May 2017 | B2 |
| 9682189 | Good et al. | Jun 2017 | B2 |
| 9687612 | Avery et al. | Jun 2017 | B2 |
| 9707339 | Chartrand | Jul 2017 | B2 |
| 9715327 | Rosinko et al. | Jul 2017 | B2 |
| 9717845 | Istoc | Aug 2017 | B2 |
| 9717848 | Geismar et al. | Aug 2017 | B2 |
| 9731067 | Pananen | Aug 2017 | B2 |
| 9744290 | Tieck et al. | Aug 2017 | B2 |
| 9744291 | Tieck et al. | Aug 2017 | B2 |
| 9744301 | Mann et al. | Aug 2017 | B2 |
| 9750871 | Metzmaker et al. | Sep 2017 | B2 |
| 9750873 | Brown et al. | Sep 2017 | B2 |
| 9750875 | Smith et al. | Sep 2017 | B2 |
| 9770553 | Bazargan et al. | Sep 2017 | B2 |
| 9782543 | Groeschke et al. | Oct 2017 | B2 |
| 9789245 | Tieck et al. | Oct 2017 | B2 |
| 9795732 | Trock et al. | Oct 2017 | B2 |
| 9801787 | Py | Oct 2017 | B2 |
| 9814830 | Mernoe et al. | Nov 2017 | B2 |
| 9814872 | Eggert et al. | Nov 2017 | B2 |
| 9839741 | Yavorsky et al. | Dec 2017 | B2 |
| 9841014 | Yap et al. | Dec 2017 | B2 |
| 9863837 | Rule et al. | Jan 2018 | B2 |
| 9872957 | Causey et al. | Jan 2018 | B2 |
| 9883834 | Amirouche et al. | Feb 2018 | B2 |
| 9889256 | Cabiri et al. | Feb 2018 | B2 |
| 9895490 | Kow et al. | Feb 2018 | B2 |
| 9925330 | Tieck et al. | Mar 2018 | B2 |
| 9931459 | Tieck et al. | Apr 2018 | B2 |
| 9931460 | Tieck et al. | Apr 2018 | B2 |
| 9943645 | Monirabbasi et al. | Apr 2018 | B2 |
| 9950113 | Franke et al. | Apr 2018 | B2 |
| 9987420 | Pananen | Jun 2018 | B2 |
| 9993592 | Amirouche et al. | Jun 2018 | B2 |
| 9993594 | Bazargan et al. | Jun 2018 | B2 |
| 10010674 | Rosinko et al. | Jul 2018 | B2 |
| 10010678 | Schildt et al. | Jul 2018 | B2 |
| 10016564 | Piehl et al. | Jul 2018 | B2 |
| 10029045 | Smith et al. | Jul 2018 | B2 |
| 10064993 | Mernoe et al. | Sep 2018 | B2 |
| 10071200 | Alderete et al. | Sep 2018 | B2 |
| 10080839 | Cole et al. | Sep 2018 | B2 |
| 10086133 | Pananen et al. | Oct 2018 | B2 |
| 10086134 | Pananen et al. | Oct 2018 | B2 |
| 10092701 | Johansen et al. | Oct 2018 | B2 |
| 10105483 | Mernoe | Oct 2018 | B2 |
| 10105497 | Dreier et al. | Oct 2018 | B2 |
| 10130759 | Amirouche et al. | Nov 2018 | B2 |
| 10130763 | Lauchard et al. | Nov 2018 | B2 |
| 10137243 | Wang et al. | Nov 2018 | B2 |
| 10141882 | Favreau | Nov 2018 | B2 |
| 10146911 | Trock | Dec 2018 | B2 |
| 10166327 | Tieck et al. | Jan 2019 | B2 |
| 10172998 | Tieck et al. | Jan 2019 | B2 |
| 10172999 | Tieck et al. | Jan 2019 | B2 |
| 10207047 | Estes | Feb 2019 | B2 |
| 10213549 | Amirouche et al. | Feb 2019 | B2 |
| 10220143 | Moberg et al. | Mar 2019 | B2 |
| 10228663 | Favreau | Mar 2019 | B2 |
| 10232109 | Deak et al. | Mar 2019 | B2 |
| 10238030 | Urbani | Mar 2019 | B2 |
| 10238793 | Deak et al. | Mar 2019 | B2 |
| 10252001 | Geismar et al. | Apr 2019 | B2 |
| 10258736 | Metzmaker et al. | Apr 2019 | B2 |
| 10272196 | Smith et al. | Apr 2019 | B2 |
| 10279110 | Mann et al. | May 2019 | B2 |
| 10300264 | Halili et al. | May 2019 | B2 |
| 10307536 | Causey et al. | Jun 2019 | B2 |
| 10322227 | Piehl et al. | Jun 2019 | B2 |
| 10363365 | Bazargan | Jul 2019 | B2 |
| 10376631 | Tieck et al. | Aug 2019 | B2 |
| 10376632 | Tieck et al. | Aug 2019 | B2 |
| 10384013 | Krusell et al. | Aug 2019 | B2 |
| 10391257 | Piehl et al. | Aug 2019 | B2 |
| 10478554 | Bazargan et al. | Nov 2019 | B2 |
| 10517892 | Chattaraj et al. | Dec 2019 | B2 |
| 10532156 | Istoc | Jan 2020 | B2 |
| 10552580 | Bazargan | Feb 2020 | B2 |
| 10603431 | Mernoe et al. | Mar 2020 | B2 |
| 10772796 | Kavazov | Sep 2020 | B2 |
| 10850032 | Steck et al. | Dec 2020 | B2 |
| 10857287 | Damiano et al. | Dec 2020 | B2 |
| 10861591 | Grosman et al. | Dec 2020 | B2 |
| 10881789 | Damiano et al. | Jan 2021 | B2 |
| 10960136 | Palerm et al. | Mar 2021 | B2 |
| 20020019608 | Mason | Feb 2002 | A1 |
| 20020038392 | De La Huerga | Mar 2002 | A1 |
| 20020055711 | Lavi et al. | May 2002 | A1 |
| 20020065484 | Douglas | May 2002 | A1 |
| 20020161332 | Ramey | Oct 2002 | A1 |
| 20030009133 | Ramey | Jan 2003 | A1 |
| 20050015056 | Duchon et al. | Jan 2005 | A1 |
| 20050020980 | Inoue | Jan 2005 | A1 |
| 20050038387 | Kriesel | Feb 2005 | A1 |
| 20050051580 | Ramey | Mar 2005 | A1 |
| 20050154434 | Simon et al. | Jul 2005 | A1 |
| 20050256461 | DiFiore | Nov 2005 | A1 |
| 20060264908 | Ishii et al. | Nov 2006 | A1 |
| 20070088271 | Richards | Apr 2007 | A1 |
| 20070142786 | Lampropoulos et al. | Jun 2007 | A1 |
| 20070161955 | Bynum et al. | Jul 2007 | A1 |
| 20070273671 | Zadesky et al. | Nov 2007 | A1 |
| 20070282294 | Sidler | Dec 2007 | A1 |
| 20080051719 | Moberg | Feb 2008 | A1 |
| 20080188813 | Miller et al. | Aug 2008 | A1 |
| 20080243085 | DeStefano | Oct 2008 | A1 |
| 20080262425 | Mogensen | Oct 2008 | A1 |
| 20080319383 | Byland | Dec 2008 | A1 |
| 20090326506 | Hasegawa et al. | Dec 2009 | A1 |
| 20100049144 | McConnell et al. | Feb 2010 | A1 |
| 20100145303 | Yodfat | Jun 2010 | A1 |
| 20100191165 | Appling et al. | Jul 2010 | A1 |
| 20100217241 | Mann et al. | Aug 2010 | A1 |
| 20110021905 | Patrick et al. | Jan 2011 | A1 |
| 20110118659 | Maaskamp | May 2011 | A1 |
| 20110230838 | Adams et al. | Sep 2011 | A1 |
| 20110288494 | Mendels | Nov 2011 | A1 |
| 20120078185 | Smith | Mar 2012 | A1 |
| 20120078197 | O'Connor et al. | May 2012 | A1 |
| 20120211946 | Halili et al. | Aug 2012 | A1 |
| 20120211947 | Halili et al. | Aug 2012 | A1 |
| 20120215177 | Halili et al. | Aug 2012 | A1 |
| 20120215178 | Halili et al. | Aug 2012 | A1 |
| 20120215179 | Halili et al. | Aug 2012 | A1 |
| 20120215180 | Halili et al. | Aug 2012 | A1 |
| 20120215183 | Halili et al. | Aug 2012 | A1 |
| 20120226234 | Bazargan et al. | Sep 2012 | A1 |
| 20130046253 | Yavorsky et al. | Feb 2013 | A1 |
| 20130085470 | O'Connor et al. | Apr 2013 | A1 |
| 20130245604 | Kouyoumjian et al. | Sep 2013 | A1 |
| 20130345641 | German | Dec 2013 | A1 |
| 20150057615 | Mernoe, V et al. | Feb 2015 | A1 |
| 20150073384 | Limaye | Mar 2015 | A1 |
| 20150202375 | Schabbach et al. | Jul 2015 | A1 |
| 20150265826 | Dudley | Sep 2015 | A1 |
| 20150314063 | Nagar et al. | Nov 2015 | A1 |
| 20150357683 | Lohr | Dec 2015 | A1 |
| 20160015885 | Pananen et al. | Jan 2016 | A1 |
| 20160015886 | Pananen et al. | Jan 2016 | A1 |
| 20160015887 | Pananen et al. | Jan 2016 | A1 |
| 20160015911 | Bazargan et al. | Jan 2016 | A1 |
| 20160051760 | Krusell et al. | Feb 2016 | A1 |
| 20160058668 | Metzmaker et al. | Mar 2016 | A1 |
| 20160074587 | Searle et al. | Mar 2016 | A1 |
| 20160082182 | Gregory et al. | Mar 2016 | A1 |
| 20160089493 | Crouther et al. | Mar 2016 | A1 |
| 20160106919 | Hayter et al. | Apr 2016 | A1 |
| 20160184519 | Blundred | Jun 2016 | A1 |
| 20160220754 | Shaanan et al. | Aug 2016 | A1 |
| 20160263324 | Shaanan et al. | Sep 2016 | A1 |
| 20160271322 | Ramey | Sep 2016 | A1 |
| 20160361494 | Jurg et al. | Dec 2016 | A1 |
| 20170056590 | DiPerna | Mar 2017 | A1 |
| 20170065768 | Moore | Mar 2017 | A1 |
| 20170182307 | Halili et al. | Jun 2017 | A1 |
| 20170189666 | Sealfon et al. | Jul 2017 | A1 |
| 20170192506 | Andersen et al. | Jul 2017 | A1 |
| 20170216523 | Neftel et al. | Aug 2017 | A1 |
| 20170235920 | Bauss et al. | Aug 2017 | A1 |
| 20170239422 | Kodgule et al. | Aug 2017 | A1 |
| 20170286638 | Searle et al. | Oct 2017 | A1 |
| 20170312454 | Chattaraj et al. | Nov 2017 | A1 |
| 20180036475 | Lin | Feb 2018 | A1 |
| 20180043104 | Mueller-Pathle | Feb 2018 | A1 |
| 20180043105 | Nazzaro et al. | Feb 2018 | A1 |
| 20180103897 | Amirouche | Apr 2018 | A1 |
| 20180104417 | Nessel et al. | Apr 2018 | A1 |
| 20180117248 | Cabiri et al. | Jun 2018 | A1 |
| 20180117296 | Damiano et al. | Jun 2018 | A1 |
| 20180207366 | Marcoz et al. | Jul 2018 | A1 |
| 20180228979 | Schildt et al. | Aug 2018 | A1 |
| 20180280624 | Bitton et al. | Oct 2018 | A1 |
| 20180311435 | Galasso | Nov 2018 | A1 |
| 20180318498 | Grant et al. | Nov 2018 | A1 |
| 20180318506 | Oakes et al. | Nov 2018 | A1 |
| 20180326164 | Bauss et al. | Nov 2018 | A1 |
| 20180353699 | Helmer et al. | Dec 2018 | A1 |
| 20190001060 | Gylleby et al. | Jan 2019 | A1 |
| 20190009032 | Hautaviita et al. | Jan 2019 | A1 |
| 20190015582 | Naftalovitz et al. | Jan 2019 | A1 |
| 20190030247 | Edwards et al. | Jan 2019 | A1 |
| 20190054251 | Pieronek et al. | Feb 2019 | A1 |
| 20190091460 | Yavorsky et al. | Mar 2019 | A1 |
| 20190134305 | Srinivasan et al. | May 2019 | A1 |
| 20190151559 | Byerly et al. | May 2019 | A1 |
| 20190167900 | Friedli et al. | Jun 2019 | A1 |
| 20190192762 | Metzmaker et al. | Jun 2019 | A1 |
| 20190209775 | Merchant | Jul 2019 | A1 |
| 20190217007 | Sasaki | Jul 2019 | A1 |
| 20200330719 | Segal | Oct 2020 | A1 |
| 20210030949 | Damiano et al. | Feb 2021 | A1 |
| 20210030957 | Damiano et al. | Feb 2021 | A1 |
| 20210106750 | Damiano et al. | Apr 2021 | A1 |
| 20210283328 | Damiano et al. | Sep 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 106061528 | Oct 2016 | CN |
| 2 678 056 | Jan 2014 | EP |
| 3 060 276 | Aug 2016 | EP |
| 3 060 277 | Aug 2016 | EP |
| 3 062 841 | Sep 2016 | EP |
| 3 150 241 | Jun 2018 | EP |
| 3 378 516 | Sep 2018 | EP |
| 3 319 662 | Mar 2019 | EP |
| 1230529 | Dec 2017 | HK |
| 1254602 | Jul 2019 | HK |
| 57-124151 | Aug 1982 | JP |
| 59-30241 | Feb 1984 | JP |
| 2004-538118 | Dec 2004 | JP |
| 2007-511252 | May 2007 | JP |
| 2013-524905 | Jun 2013 | JP |
| 2014-515673 | Jul 2014 | JP |
| 2016-538098 | Aug 2016 | JP |
| 2018-525060 | Sep 2018 | JP |
| 2549310 | Apr 2015 | RU |
| WO 9964103 | Dec 1999 | WO |
| WO 04045704 | Jun 2004 | WO |
| WO 05004973 | Jan 2005 | WO |
| WO 06054367 | May 2006 | WO |
| WO-2007075677 | Jul 2007 | WO |
| WO 09069511 | Apr 2009 | WO |
| WO 07086186 | May 2009 | WO |
| WO 09060741 | May 2009 | WO |
| WO 12008285 | Jan 2012 | WO |
| WO 12072555 | Jun 2012 | WO |
| WO 12110474 | Aug 2012 | WO |
| WO 120115911 | Aug 2012 | WO |
| WO 12160104 | Nov 2012 | WO |
| WO 13161979 | Oct 2013 | WO |
| WO 14104027 | Mar 2014 | WO |
| WO 15061690 | Apr 2015 | WO |
| WO 15061691 | Apr 2015 | WO |
| WO 15061693 | Apr 2015 | WO |
| WO 15155229 | Oct 2015 | WO |
| WO 15166993 | Nov 2015 | WO |
| WO 17007968 | Jan 2017 | WO |
| WO 17199012 | Nov 2017 | WO |
| WO 17217105 | Dec 2017 | WO |
| WO 18129354 | Jul 2018 | WO |
| WO 19021985 | Jan 2019 | WO |
| WO 19046593 | Mar 2019 | WO |
| Entry |
|---|
| Kolind et al., “Preservation-free drug for insulin pumps,” Novo Nordisk Pharmaceutical company, Pump partner meeting ATTD 2020, WOP Technology Presentation, 26 pages. |
| Ping One Touch Owner's Booklet, Dated Oct. 2014, (360 pages). |
| Renesas Synergy™ Platform, “Capacitive Touch Hardware Design and Layout Guidelines for Synergy, RX200, and RX100.” R01AN3825EU0101 Rev.1.01, Jun. 14, 2017, pp. 1-18. |
| International Preliminary Report on Patentability, PCT/US2014/062187, dated Apr. 26, 2016, 6 pages. |
| International Preliminary Report on Patentability, PCT/US2014/062189, dated Apr. 26, 2016, 7 pages. |
| International Preliminary Report on Patentability, PCT/US2014/062186, dated Apr. 26, 2016, 6 pages. |
| International Search Report and Written Opinion, PCT2014/062186, dated Feb. 18, 2015, 9 pages. |
| International Search Report and Written Opinion, PCT2014/062187, dated Feb. 24, 2015, 10 pages. |
| International Search Report and Written Opinion, PCT2014/062189, dated Feb. 24, 2015, 11 pages. |
| Boston University, Jan. 2014, Bionic Pancreas: Introducing the iLet 1294 1000, http://sites.bu.edu/bionicpacreas/introducing-the-ilet-1294-1000/, 3 pp. |
| Brown et al., Apr. 1, 2016, Introducing Beta Bionics: bringing the iLet bionic pancreas to market, https://diatribe.org/introducing-beta-bionics-bringing-ilet-bionic-pancreas-marekt, 3 pp. |
| Hoskins, Oct. 2, 2018, iLet “Bionic Pancreas” making progress with gen 4 device, Healthline, https//www.healthline.com/diabetesmine/beta-bionics-ilet-update#1, 15 pp. |
| Idlebrook, Jul. 30, 2019, Beta Bionics secures funding for pivotal ILet bionic pancreas trials, https://t1dexchange.org/welcome-glu-users/articles/beta-bionics-secures-funding-for-pivotal-ilet-bionic-pancreas-trials, 4 pp. |
| Krugman, Aug. 25, 2018, iLet Bionic Pancreas Interface, sarakrugman.com/ilet-interface, 3 pp. |
| Sifferlin, Apr. 1, 2016, The bionic pancreas is getting closer to reality, time.com, https://time.com/4278068/bionic-pancreas-company, 5 pp. |
| Number | Date | Country | |
|---|---|---|---|
| 20210093777 A1 | Apr 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61895279 | Oct 2013 | US | |
| 62011306 | Jun 2014 | US | |
| 61932835 | Jan 2014 | US | |
| 61895270 | Oct 2013 | US | |
| 61895288 | Oct 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15031512 | US | |
| Child | 17122263 | US |
